TrialLeukemia research2018

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).

Joshua F Zeidner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.